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Immune stimulationThe relationship between cancer and the immune system is a complex one. The immune system can prevent tu-
mour growth by eliminating cancer cells but this editing process ultimately results in poorly immunogenic cells
remaining allowing for unchallenged tumour growth. In light of this, the focus of cancer treatment should be to
maximise cancer elimination and the prevention of escape mechanisms. In this review we will examine current
and emerging ablative treatment modalities that induce Immunogenic Cell Death (ICD), a special type of cell
death that allows for immune cell involvement and the generation of an anti-tumour speciﬁc immune response.
When paired with immune modulating agents, capable of potentiating the immune response and reversing the
immune-suppressive environment created by tumours, we may be looking at the future of anti-cancer therapy.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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Cancer can be deﬁned as the rapid and uncontrolled growth of ma-
lignant cells in the body and even with recent advances in the areas of
detection and treatment, there were 8.2 million cancer related deaths
worldwide in 2012 [1].With anestimated 14.1million new cases of can-
cer in 2012 and projections predicting a substantial increase to 19.3mil-
lion cases per year by 2025 [1], the need for more effective treatments
has never been higher. With this is mind there has been renewed inter-
est in the immune system, its relationship with cancer and the ability to
harness its potential for ﬁghting the disease.
The main function of the immune system is to protect us against in-
vading pathogens; it detects these pathogens via a set of pattern recog-
nition receptors (PRRs) that bind pathogen-associated molecular
patterns (PAMPs) [2]. PAMPs include viral RNA, the components of bac-
terial cell walls and, when detected trigger the activation of the innate
immune system to protect the host [3]. However not all threats come
in the form of invading bacterial/viral organisms and so the immune
system has developed the ability to identify and eliminate cancerous/
transformed cells. Two landmark murine studies demonstrated the im-
portance of a functional immune system in preventing carcinogenesis;
mice lacking IFN-γ responsiveness or speciﬁc immune cells (T cells, B
cells and NK cells)weremore susceptible to chemically induced tumour
formation [4,5]. Lung and kidney transplant patients are put on immu-
nosuppressive drugs (cyclosporine A, corticosteroids, azathioprine,
etc.) to prevent against transplant rejection, and the fact that these
patients have been shown to have a higher chance of developing neo-
plastic malignancies, reinforces the protective importance of the im-
mune system [6–11]. Human immunodeﬁciency virus (HIV) and the
subsequent acquired immunodeﬁciency syndrome (AIDs) result in de-
pletion of CD4+ T cells and leave patients severely immunocompro-
mised [12]. It is no coincidence that HIV/AIDs sufferers have increased
incidences of cancer [13–15] and in fact several cancers (Kaposi's sarco-
mas, cervical cancer and non-Hodgkin's lymphoma) are now commonly
deemed AIDs deﬁning malignancies [16–18]. Subsequent work in the
ﬁeld has shown that ‘immuno-surveillance’ is only one aspect of the
complex relationship between the immune system and cancer [19]
and has led to formation of the ‘cancer immuno-editing’ hypothesis.2. Cancer immuno-editing
Cancer immuno-editing is a reﬁnement on the original ‘immuno-
surveillance’ idea and suggests that the immune system not only pro-
tects the host against cancer, but also shapes tumour immunogenicity
(the ability for the tumour to provoke an immune response). Murine
studies have shown that tumours that develop in immune-competent
mice (deemed ‘edited’ tumours) often grow more easily than tumours
that originate from immunocompromised mice (‘unedited’), when
transplanted into syngeneic immune-competent mice [5]. Therefore
the immune system not only protects the host against tumour forma-
tion but also applies selection pressure favouring the development of
less immunogenic tumours, which escape recognition by a functioning
immune system. Immuno-editing is deemed to have 3 phases, each of
which we will examine further.2.1. Elimination
The innate immune system acts as our body's ﬁrst line of defence and
its main components are dendritic cells (DCs), macrophages and mono-
cytes, neutrophils, natural killer (NK) cells, and natural killer T (NKT)
cells. NK cells are important in the early stages of cancer elimination;
they have the ability to recognize stress induced ligands such as
NKG2D-L, through their NKG2D receptors. The NKG2D ligands can be in-
duced on tumour cells through DNA damage [20] and other stimuli,
alerting NK cells to unwanted transformation [21]. NK cells' ability to
eliminate tumour cells is dependent on the expression of tumour cell
p53, a consequence of the cellular DNA damage response [22], which
leads to the secretion of various interleukins and cytokines that recruit
NK cells to the tumour site [23]. Tumours lacking p53 expression can
evade NK mediated clearance but when p53 activity is restored, the tu-
mour cells are gradually cleared by NK cells and other inﬁltrating cells
[24]. Upon activation, NK cells secrete interferon-γ (IFN-γ), a type II cy-
tokine critical to the initial immune response. IFN-γ up-regulates pro-
duction of the cytolytic protein perforin [25] as well as the apoptotic
inducing Fas ligand [26] and TNF-related apoptosis-inducing ligand
(TRAIL) [27]. IFN-γ has also been shown to protect against the growth
of transplanted tumours [28], to activate dendritic cells and promote
the generation of tumour-speciﬁc CD4+ T and CD8+ T cells [29], and to
augment major histocompatibility complex (MHC) expression on tu-
mour cells [30]. These functions are crucial in improving tumour immu-
nogenicity and potentiating the activity of both the innate and adaptive
immune responses. Type I interferons (IFN-α/β) have an important
role in the immune-editing process; in fact IFN-α is the most used cyto-
kine in patients, used to treat a wide range of cancerous malignancies
[31]. IFN-α/β can up-regulate the p53 mediated response of tumour
cells to DNA damage [32] but it seems that their major contribution to
anti-cancer immunity is their actions on haematopoietic cells. Type I
IFNs are important for the in vivo proliferation and long-term survival
of anti-TAA (tumour speciﬁc antigens) speciﬁc CD8+ T cells [33] and
they also enhance the expression of anti-apoptotic genes in human T
cells [34]. Dendritic cells (DCs) are often regarded as the most effective
of the antigen presenting cells (APCs) and type I IFNs have important ef-
fects onDCdifferentiation andmaturation [35,36]. As such type I IFNs are
often thought of as an important link between the innate and adaptive
arms of the immune system.
Adaptive immunity consists of T and B lymphocytes and their re-
spectivemediators (cytokines and antibodies) and its ability to generate
an immune ‘memory’. It is the interplay and communication between
both arms of the immune system that make it effective against cancer
functional cytotoxic CD8+ (CTL) and helper CD4+ T (TH1) cells are
critical for the eradication of cancerous cells. The T cell receptor (TCR)
of cytotoxic CD8+ T cells is capable of binding with the MHC-1 mole-
cule of harmful/cancerous cells or antigen presenting cells (APC) and
causes subsequent cellular lysis through the release of perforin,
granzymes and granulysin. Once activated, the CD8+ T cells undergo
rapid clonal expansion, aided by the MHC-II/TCR mediated secretion
of IL-2 from the CD4+ T helper cells, which is a potent growth and dif-
ferentiating factor. Higher numbers of total circulating and tumour inﬁl-
trating CD8+ and CD4+ T cells are associated with improved
prognosis/survival in patients with various cancer types [37–39]. T
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the T cell population and have cytotoxic activity against a wide range of
cancers [40]. More importantly, γδ T cells secrete IFN-γ and attract acti-
vated lymphocytes and APCs through the secretion of a number of
chemokines [41,42]. Mice lacking γδ T cells are more susceptible to
chemically-induced tumour formation than wild-type mice [43]. The
generation of a robust anti-cancer immune response following chemo-
therapy and effectiveness of the chemotherapy itself has been found
to be dependent on γδ T cells and their secretion of the effector cyto-
kine; IL-17 [44].
2.2. Equilibrium
Tumour cell variants that survive the elimination phase are then
proposed to enter the equilibrium phase. This phase is the least well
understood of the three but the generally accepted theory is that the in-
tense pressure endured by the cancer cells during the elimination phase
leads to genetic selectivity in the surviving cells, resulting in a surviving
population with reduced immunogenicity. This ‘dormant’ population
may be held in check by the immune system for years before returning
as recurrent disease at the site of the primary tumour or possibly as
distal metastases [45]. Experimental evidence for the existence of equi-
librium is mostly based on murine studies. In one such study, mAb me-
diated T cell/ IFN-γ depletion in immuno-competent mice with
chemically induced, stable tumours, resulted in rapid tumour growth
[46]. In another similar study it was shown that the balance between
IL-12 (a cytokine with anti-tumour properties) and IL-23 (a cytokine
with tumour promoting properties) was found to hold chemically in-
duced tumours in a state of equilibrium [47]. Examining themicroenvi-
ronment of tumours deemed to be in this state of equilibrium or
dormancy, one study found high numbers of CD8+ T cells, NK cells,
and γδ T cells and low proportions of FOXP3+ Treg cells, and MDSCs,
indicating a balance between anti-cancer and pro-cancer immune
cells [48].
2.3. Escape
Tumour cells that have survived the elimination phase and passed
through the equilibrium phase of the cancer immuno-editing process
will have undergone intense selectivity and possess the tools necessary
to escape the control of the immune system. One method used by can-
cer cells to create an immunosuppressive environment is the downreg-
ulation of MHC-1; CD8+ cytotoxic T cells scan the MHC-1 molecule for
peptides whichmay be related to TAAs and induce apoptosis to prevent
the spread of the disease [49]. Downregulation of MHC-1 has been
shown in many cancer cell types [50] and has also been linked to poor
prognosis survival rates in patients with ovarian, renal cell and other
types of cancer [51–53]. One of the functions of NK cells is to identify
cells lacking MHC-1 expression and subject them to NK-mediated cell
death [54]. For NK cells to be effective, they require the presence of ac-
tivation receptors and ligands, of which the NKG2D receptor and its
ligand (NKG2D-L) are the most vital. However NKG2D and NKG2D-L
are down-regulated in many cancer types and this too is an indicator
of poor prognosis [55–57]. In contrast, higher numbers of circulating
and tumour inﬁltratingNK cells correlatewith better prognosis and sur-
vival in pancreatic, lung and gastric cancers [58–60].
Immune inhibitory receptors such as Cytotoxic T-Lymphocyte Anti-
gen 4 (CTLA-4) and Programmed Death 1 (PD-1), which are expressed
on the surface of activated T cells, can effectively shut down T cell
activity upon binding to their ligands CD80/CD86 and PD-L1/PD-L2 re-
spectively. The complex interplay between these stimulatory and inhib-
itory mechanisms has been shown to be crucial in the immune
mediated elimination of cancer [61]. For example increased expression
of PD-L1 is associated with decreased T cell activity, inﬁltration and
poorer prognosis in many cancers [62–65]. Similar correlations have
been found in melanoma patients expressing higher levels of CTLA-4receptor and its ligands [66]. Regulatory T cells (Tregs), a type of T cell
that suppresses exaggerated and prolonged immune responses, have a
very negative impact on tumour elimination by promoting an immuno-
suppressive environment [67,68]. Increased Tregs at the tumour site
correlates with more advanced disease and poorer prognosis [69–72]
while low Treg percentage correlates with improved survival [72,73].
3. The abscopal effect & immunogenic cell death
In light of this complex relationship between the host immune sys-
tem and cancer, emphasis should be placed onmaximising ‘Elimination’
and preventing ‘Escape’ mechanisms when applying interventions or
developing new treatments. While most conventional treatment mo-
dalities (radiation, chemotherapy) were once thought to induce cancer
cell death in an immune independent manner, however this is not the
case.
3.1. The abscopal effect
There are a number of physical ablative modalities and chemothera-
peutics which have caused regression in tumours that are distal to the
primary site of treatment [74]. This has been observed in more than
one type of cancer [75–77] and strongly indicates that immunemecha-
nisms are involved. This phenomenon has been termed the ‘Abscopal
Effect’ and has been a topic of interest since the 1950s; however the
mechanism of action still remains unclear. A number of theories have
been put forward, including the importance of certain cytokines [78,
79], NK cells [80,81] and functional T cell populations [82] in the gener-
ation of an abscopal effect, all ofwhich point towards a link between the
immune system and the abscopal effect. Murine data has also highlight-
ed the importance of the transcription factor, p53, and its role in apopto-
sis in the abscopal effect [83]. In addition to those mentioned above,
another postulated mechanism of the abscopal effect is the release of
‘tumour associated antigens’ (TAAs) caused by treatment at the primary
site and the subsequent activation of the immune system due to ‘danger
signals’ [84]. This concept is closely related to the “danger”model of im-
munity originally proposed byMatzinger in 1994 [85].While the under-
standing of the abscopal effect is still incomplete at best, it does have
interesting parallels with immunogenic cell death, a type of cell death
that induces a positive immune response through the release of damage
associatedmolecular proteins (DAMPs) [86].Whether ICD plays a direct
role inmediating the abscopal effect is yet to be determined but it could
go a long way to explaining the phenomenon.
3.2. Immunogenic cell death & DAMPs
The term Immunogenic Cell Death (ICD) was coined to describe cell
death that stimulates immune cells in the tumour environment and
results in a favourable anti-cancer host immune response. Whether a
dying cell can be described as undergoing ICD, depends on a number
of factors; the activation state of the cell is one such criteria [87]. The
type of cellular stress is another differentiator; the DNA-damage-
response and endoplasmic reticulum (ER) stress are two speciﬁc
examples known to elicit immunogenic responses [20,88]. Caspase acti-
vation is also important, as inhibiting caspase activity can prevent the
mobilisation of immuno-epitopes within the cell also inhibits certain
signals, key to the ICD response [89]. However the release of DAMPs
from dying cells is probably the most important factor characterizing
ICD as DAMPs are the key mediator in causing the ICD related immune
response generated by stressed or dying cancerous cells [90].
DAMPs are intracellular molecules that when exposed on the cell
surface or secreted extracellularly, induce a potent pro-inﬂammatory
immune response. These molecules can exert various beneﬁcial effects
on APCs, including activation, maturation and antigen processing/
presentation. The emission of DAMPs was initially thought to be exclu-
sively related to necrosis that occurred due to physical or chemical
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acute cellular injury and involves the rupture of the cell's plasma
membrane and the destruction of the intracellular organelles [92].
More recently however, DAMPs have been shown to be secreted from
apoptotic cells too [93]. Apoptosis can be thought of as a programmed
or controlled type of cell death, commonly characterized by the caspase
activation and the permeabilization of the mitochondrial membrane
[94,95].
Many different DAMPs have been identiﬁed and their presentation/
exposure to the immune system depends on the cancer treatment used
and the mechanism of cancer cell death involved. Some of the key
DAMPs involved in immunogenic cell death and how they interact
with immune cells, are detailed below and visually outlined in Fig. 1.
3.3. DAMPs
3.3.1. Calreticulin
Calreticulin (CRT) is a highly conserved, Ca2+ binding chaperone
protein, mainly located in the lumen of endoplasmic reticulum (ER)
and plays a key role in the activity and regulation of Ca2+ homeosta-
sis/signalling and through the interaction with the isomerase ERp57,
CRT facilitates proper folding of ER-chaperoned proteins [96]. CRT also
aids in the correct assembly of MHC-1 molecules and insures effective
loading of antigens [97]. CRT that is found on the plasma membrane
cells, plays an important role in ICD by signalling phagocytes to engulf
dying cells [98]. CRT translocates to the cell surface via a number ofFig. 1. Interaction between the cells of the immune systemandDAMPs released fromdying tumo
receptors on APCs, which increases the amount of TAAs processed and presented to T cells by p
on the surface of dying cells, via various pathways, effectivelymarks them for engulfment by AP
to the T cells. c) HSPs can bind to many surface receptors on APCs, including endocytic receptor
ulation of the antigen presenting molecules MHC-1 andMHC-II. d) Extracellular ATP binds to pu
of pro-inﬂammatory cytokines to promote T cell activity.mechanisms, depending on the stage of cell death. Pre-apoptotic ecto-
CRT expression relies on PERK mediated translocation and the PI3K
distal secretory pathway, while later stages of apoptosis involve co-
exposure with phosphatidylserine and binding with lipid rafts on the
plasma membrane [98–100].
Ecto-CRT is upregulated during cellular apoptosis and several con-
ventional cancer treatments including radiotherapy, anthracyclines
and platinum based chemotherapeutics, have the ability to increase
ecto-CRT exposure [101–103]. This is favourable as the ecto-CRT has
been shown topromote the engulfment of apoptotic cells by profession-
al phagocytes (e.g. macrophages and DCs), through binding and activa-
tion of the CD91 receptor (also called the LDL-receptor related protein
or LRP) on the phagocytes [98]. This allows APCs to process and present
TAAs from the engulfed cells to CD8+ and CD4+ T cells through their
MHC-1 molecules. CRT exposed on the surface of dying cancer cells is
essential for the immunogenicity of apoptosis, without which the
resulting cell death would go un-noticed by the immune system and
is effectively ‘silent’. Anti-cancer vaccines that rely on dying tumour
cells for their efﬁcacy have been shown to be ineffective when ecto-
CRT function is neutralized through CRT-speciﬁc antibodies or siRNA-
mediated CRT, when exogenous CRT was then re-administered the ef-
fects of the vaccination were restored [101,104]. When all of this is
taken into account, ecto-CRT can effectively be thought of as an ‘eat
me’ signal for professional phagocytes. Increased CRT expression is
deemed to be a positive prognostic factor in patients with gastric cancer
and neuroblastoma [105,106].ur cells. a)HMGB-1 released fromdying cell has the ability to bind to RAGE, TLR2 and TLR4
reventing the degradation of TAAs in the lysosomes of APCs. b) The expression of ecto-CRT
Cs, and the contents of the tumour cell (including TAAs) are then processed and presented
s and immune signalling receptors. This leads to increased tumour cell uptake and up-reg-
rigenic receptors on APCs, activating the NLRP-3 inﬂammasome and causing the secretion
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In healthy cells HighMobility Group Box 1 Protein (HMGB1) is local-
ized in the nucleus and binds to chromatin and inﬂuences transcription
and other nuclear functions [107]. While CRT is exposed on the plasma
membrane early in the apoptosis process, HMGB1 is secreted extracel-
lularly during 1° necrosis and late apoptosis (2° necrosis) [108–110].
Within the cell, HMGB1 has several important ‘pro-survival’ functions,
such as mediating autophagy, aiding with transcription and the assem-
bly of protein complexes within the nucleus [110,111]. Outside of the
cell, the function of HMGB1 is drastically different and can be thought
to act like a pro-inﬂammatory ‘cytokine’. Studies have shown the im-
portance of HMGB1 in chemotherapy and radiotherapy mediated cell
death, implicating it as one of the molecules involved in ICD and the
abscopal effect [112,113]. HMGB1 has been shown to play a powerful
role in the activation of APCs and is known to bind to at least three dif-
ferent pattern recognition receptors (PRRs) expressed on APCs; namely
the receptor for advanced glycosylation (RAGE), TLR2 and TLR4 [114,
115]. TLR4 (Toll like receptor 4) controls antigen presentation in APCs
by preventing the fusion of phagosomes with lysosomes, allowing
TAAs within the phagosome to form into tumour antigen peptides
that can be presented to the other cells of the immune system via the
APC's MHC molecules [116]. Without TLR4 activation through HMGB1
binding, the TAAs engulfed by the APCs would be degraded by fusion
with lysosomes, rendering the cell death non-immunogenic [117]. The
signiﬁcance of the HMGB1/TLR4 relationship in chemotherapeutic or
radiotherapy induced ICD is further emphasised by several studies
across multiple cancer types. Neutralization or knockdown of HMGB1
and/or knockout of TLR4 inhibits the initiation of a pro-inﬂammatory
immune response and the priming of T cells [112,113,118]. However
the picture of HMGB1 as a potent anti-cancer DAMP is being challenged
by recent studies showing that in certain circumstances it can promote
tumour angiogenesis, as well as invasion and metastasis [115,119].
Therefore HMGB1 can be viewed as having context dependent
functions, with intracellular HMGB1 being pro-survival and even pro-
tumourigenic, while extracellular HMGB1 has anti-tumourigenic
functions.
3.3.3. Heat shock proteins
Heat shock proteins (HSPs) are a family of highly conserved chaper-
one proteins that play an important role in folding of newly synthesized
proteins and also in the refolding of proteins in response to cellular
stress [120]. Similarly to CRT, HSPs are expressed intracellularly in
healthy cells but can be induced to translocate to the plasmamembrane
(ecto-HSP) under stressful conditions. This has been observed with
platinum based chemotherapeutic drugs [102,121] as well as several
ablative modalities, including; radiofrequency ablation, thermal abla-
tion and ultrasound ablation [122–124].While intracellular overexpres-
sion of HSPs causes cyto-protection and inhibits apoptosis [125], extra-
cellular expression of HSPs during late apoptosis and necrosis can elicit
immune-stimulatory effects [126].
Ecto-hsp70, ecto-hsp90 and gp96may play a role in ICD due to their
ability to interact with a number of endocytic promoting surface recep-
tors on APCs (CD91 and LOX1) [127,128] and also several signalling re-
ceptors (CD40, TLR2 and TLR4) [129,130]. This causes the up-regulation
of manymaturationmarkers such as CD86 and CD40 [129,131,132] and
consequently improves the cross-presentation of TAAs to CD8+ and
CD4+T cells through up-regulation of theMHC-I andMHC-IImolecules
[133]. Activation at these receptors results in the secretion of many pro-
inﬂammatory cytokines which are key for an optimum immune re-
sponse; these include tumour necrosis factor-α (TNF-α), IL-1β, IL-12
and GM-CSF [129,134]. The translocation of NF-κβ transcription factor
to the nucleus of APCs and its subsequent activation due to the above
stimuli, further drive the transcription of other pro-inﬂammatory cyto-
kines and growth factors required for immune cell activation and differ-
entiation [129,135]. Vaccination with HSPs, isolated from tumour
stressed tumour lysates has shown the ability to induce a speciﬁc anti-tumour immune response [136]. The fact that HSPs derived from
damaged/stressed tumour tissue are more immune-stimulatory than
exogenous recombinant HSPs, suggests that HSPs may actually form
complexes with TAAs and it is this complex that accounts for their
immune-stimulating abilities [137].
3.3.4. Adenosine triphosphate
Adenosine Triphosphate (ATP) is a ubiquitous intracellular metabo-
lite; it has a key role in cellular energy production and can also act as a
paracrine/autocrinemessengermolecule [138]. ATP can be released pas-
sively into the extracellular space during necrosis or via various mecha-
nisms during apoptosis [139,140]. This release of ATP from dying cells
has been shown to be caused by a number of common chemotherapeutic
agents (etoposide, mitomycin C, oxaliplatin, cisplatin and doxorubicin)
[141] and ablative methods such as radiotherapy and electroporation
[142,143]. Once released from dying cells, ATP can bind the P2Y2/P2X7
purinergic receptors on macrophages and DCs, activating the NLRP3
inﬂammasome [144,145]. NLRP3 mediates the production of the prote-
ase' caspase-1, which in turn drives the production of pro-
inﬂammatory cytokines IL-1β and IL-18 [145]. IL-1β in particular, is cru-
cial in the recruitment and functionalmaturation of both innateγδ T cells
and TAAprimedCD8+T cells [145,146]. NLRP3 function is critical for the
efﬁcacy of many chemotherapeutics and the generation of an immuno-
genic response. One study that highlighted this compared the tumour
growth of WT mice treated with oxaliplatin and mice with deﬁcient
NLRP3 inﬂammasomes or lacking IL-1β, and results showed that both
were essential for the efﬁcacy of the chemotherapy [147]. The crucial im-
portance of IL-1β in the antitumour effects of oxaliplatin was shown in
chemically induced tumours [145].
4. Tumour ablation, ICD and DAMP release
With recent research highlighting the importance of DAMP release
and ICD in immune mediated clearance of cancer, the focus now
needs to shift towards developing clinical interventions that harness
this potential. Fig. 2 illustrates that the types of DAMPs released from
dying cells depends on the cause of cell death and below we will look
at some of the established and emerging ablative technologies known
to induce ICD and/or DAMP release.
4.1. Radiation
Ultraviolet C (UVC) and ionizing radiation (radiotherapy) have both
been proven to cause DAMP release following treatment. UVC induced
ICD relies on caspase 8 signalling [99] and has been shown to cause
pre-apoptotic ecto-CRT release, as well as ATP release during early apo-
ptosis [101,145]. Ionizing radiation is more relevant as a treatment mo-
dality as it is one of the cornerstones of cancer therapy, long known for
its ability to induce cancer cell death through apoptotic and necrotic
mechanisms. Its ability to enhance tumour immunogenicity and gener-
ate an abscopal effectwas realised following numerous cases, across dif-
ferent cancer types, where distant metastases spontaneously regressed
after radiation therapy at a primary site [75,79,148,149].
Subsequent research has shown that radiation therapy causes the re-
lease of DAMPs and pro-inﬂammatory cytokines from dying cells, effec-
tively priming the immune response. Ecto-CRT, the potent ‘eatme’ signal
causingmacrophage engulfment, is expressed on the surface of dying ir-
radiated tumour cells, facilitating better TAA cross-presentation to other
immune cells [93,101]. Other DAMPs released following radiation medi-
ated cell death include HMGB1 and ATP, inﬂammatory molecules with
the ability to bind to TLRs and purinergic receptors on APCs, which also
causes TAA processing and T-cell priming following the release of IL-1β
[113,150,151]. Radiation therapy also up-regulates the expression of sev-
eral proteins with anti-cancer properties including; the Fas death recep-
tor (CD95) [152], MHC-1 [153] and the chemokine CXCL16, responsible
for the recruitment of T cells to the tumour site [154]. However, while
Fig. 2. Immunogenic Cell Death (ICD) caused by ablative modalities and subsequent DAMP release. a) Cellular stress causes CRT to migrate from ER to Golgi bodies and as apoptosis pro-
gresses; CRT is expressed on the plasmamembrane (ecto-CRT). This can be induced by radiation and ECT. b) During cellular apoptosis, ATP is actively secreted from dying cells. The loss of
membrane integrity during necrosis allows leakage of ATP into the extracellular space. Radiation and ECT have been proven to cause this ATP release. c)HMGB-1 is typically locatedwithin
the nucleus but during apoptosis it relocates to phagosomes in the cytoplasm, late stages of apoptosis and necrosis sees it expelled in the extracellular space. Ablative techniques that cause
this include cryoablation, radiation and ECT. d) Heat shock proteinsmove from intracellular compartments to the extracellular space and form complexes on the plasmamembrane as the
stages of apoptosis advance. Cellular necrosis, as caused by RFA and in some cases ECT, leads to passive diffusion of HSPs into the extracellular space.
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severely limited by its adverse side effects proﬁle. It has been known to
cause neutropenia (a condition characterized by severely low neutro-
phil count) [155], myelo-suppression (reduced production of oxygen
carrying red blood cells, immune precursor lymphocytes and platelets
in the bone marrow) [156] and production of the inhibitory cytokines
IL-6, IL-10 and TGF-β [157,158].
4.2. Radiofrequency ablation
Radiofrequency ablation (RFA) is another physical ablative method
that causes cellular necrosis by using a high frequency current to heat
and coagulate tissues, causing protein denaturation [159]. While RFA
does not cause classical ICD, the necrotic cell death can lead to a positive
immune response due to the passive release of DAMPs into the micro-
environment [122,160,161].
RFA has been used successfully to treatmany cancer types including
hepatocellular carcinoma, renal cell carcinoma and lung cancers. RFA
has been shown to cause an abscopal effect and the regression of distal
pulmonary metastases in renal cancer [82]. Other studies have
highlighted the ability of RFA to increase the activity and immune stim-
ulating abilities of APCs [162], generate tumour speciﬁc CD8+ and
CD4+ T cell responses [163] and increase the numbers of NK cells in
the tumour environment [163,164]. When coupled with a TAA derived
vaccine, RFA has shown to be very effective at causing local and distal
tumour regression [165]. The mechanism by which RFA is able tocause tumour speciﬁc systemic immune response is likely due to the
release of HSPs following RFA treatment. One of the drawbacks of RFA
is that given its method of administration, the types of tumours that
can be treated are currently limited and the margin of treatment is
also quite small. Other serious adverse effects are lethal portal vein
thrombosis, haemorrhages, liver abscesses, pleural effusion and pneu-
mothorax [166,167]. Another major concern when using RFA is tumour
seeding along the track of the needles used to deliver the current, a
highly undesirable consequence [168,169].
4.3. Cryoablation
Cryoablation uses extreme cold to cause tumour destruction. Freeze–
thaw cycles cause cellular injury by disrupting cellular metabolism, and
cell dehydration leads to protein damage and subsequent disruption of
the cell membranes. Intracellular ice crystal formation causes further
mechanical damage to organelles and cellmembranes, leading to necrot-
ic cell death [170,171]. The ability of cryoablation to induce an anti-
tumour speciﬁc immune response was ﬁrst postulated in the 1960s,
with the thinking being that cryoablation caused the release of TAAs
[172,173]. More recent research has provided a clearer insight into its
immune modulating abilities. Increased numbers of PMN leukocytes
andmacrophages are recruited to the tumourmicroenvironment follow-
ing cryoablation [174]. In a murine breast cancer model, cryoablation
was shown to protect mice from tumour re-challenge following treat-
ment of the primary tumour, indicating the generation of anti-tumour
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nism showed increased NK cell activity and increased production of IL-
12 and IFN-γ after treatment. Another study using radioactively labelled
TAAs showed increased uptake of the antigens by DCs in the lymph
nodes following cryoablation, indicating that cryoablation facilitates
improved antigen presentation and T cell priming [176]. The exact
mechanism by which cryoablation induces a favourable immune re-
sponse may be explained by the results of a recent study that showed
that cryoablation causes the extracellular release of HMGB 1 and nucle-
otides from dying cells [177]. As we know HMGB 1 has the ability to
bind with RAGE and TLRs on APCs, preventing the degradation of
TAAs by lysosomes and increasing TAA presentation via MHC-1 and
MHC-II molecules. Depending on the site of treatment, the drawbacks
of cryoablation include incontinence and erectile dysfunction (prostate)
[178], pleural effusion and pneumothorax (lung) [179].
4.4. Chemotherapy & electrochemotherapy
A number of commonly used chemotherapeutic agents have been
shown to cause ICD. Platinum based drugs, such as oxaliplatin, and vari-
ous anthracyclines (doxorubicin) have been shown to induce the release
ofmanyDAMPs, including; ecto-CRT, HSPs, ATP andHMGB1 [93,113,145,
146,180,181]. These DAMPs, as previously discussed are critical to induc-
ing ICD. In fact the anti-cancer abilities of oxaliplatin and anthracyclines
are better in immune-competent mice, than in immune-deﬁcient
athymic mice, highlighting the importance the immune system plays in
their mechanisms [93,112,113]. As well as interfering with DNA replica-
tion, cyclophosphamide can also cause dendritic cell activation through
the release of HMGB1 and ecto-CRT, which has knock-on effects in
terms of pro-inﬂammatory cytokine production and T cell proliferation
[182,183].
Mitoxantrone (MTX) is a type-II topoisomerase inhibitor that is
commonly used to treat breast cancer, leukaemia and prostate cancer
[184–186]. By disrupting DNA-replication proteins, MTX can indirectly
cause ER stress [93]. ER stress is crucial for the activation of danger sig-
nalling pathways that help to trafﬁc DAMPs to the extracellular space
[187]. Amongst the DAMPs released by MTX treatment are ecto-CRT,
ecto-HSP70, ATP and HMGB-1 [113,145,146].
Bortezomib, a proteosome inhibitor, can cause an immunological re-
sponse following treatment by activating DCs and subsequently induc-
ing an anti-tumour speciﬁc T cell response [188]. This anti-tumour
response was shown to be dependent on contact between HSP-90 ex-
posed on the surface of dying cells and DCs [188]. The ability of
bortezomib to cause ICD and DAMP release is thought to be related to
its secondary ability to generate reactive oxygen species (ROS), causing
potent cellular stress [189–191].
These capabilities become even more valuable when adding the po-
tential of electrochemotherapy (ECT) to the picture. ECT involves the ap-
plication of an electric ﬁeld to tumour tissue, resulting in temporary
formation of pores in the cell membrane (electroporation or EP) with
subsequent administration of a chemotherapeutic agent [192,193]. The
cell membrane generally acts as a physical barrier and prevents the
entry of hydrophilic drugs, molecules and peptides into the cell; the abil-
ity to render this barrier ‘permeable’ allows for the inﬂux of otherwise
non-permeable or poorly permeable anti-cancermolecules into the cyto-
sol of cancer cells. This effectively enhances the cytotoxicity of the drug
used, with platinum based chemotherapeutics (cisplatin) exhibiting a
70 fold increase in efﬁcacy when used as part of electrochemotherapy
treatment [194]. Given the ability of platinum based drugs to induce
ICD through the release of DAMPs, this increase in cytotoxicity is very de-
sirable. Another compound frequently used as part of ECT, bleomycin, has
displayed the ability to induce ICD in vitro. Bleomycin is a glycopeptide
that causes DNA strand breaks, inhibits replication and generates ROS
in the process, resulting in oxidative cellular stress [195,196]. Bleomycin
as a stand-alone agent has caused ICD in a murinemodel [197], however
when combined with EP, as part of an ECT regime, the activity ofbleomycin is increased 700 fold [198]. ECTwith bleomycin causes the re-
lease of HMGB1 from dying cells [199], and interestingly, the same study
showed that application of electric pulses alonewas enough to cause ATP
release and extracellular CRT expression on treated cells [199]. Therefore
ECT can be thought of as a tool to enhance the effect of other ICD inducers,
facilitating their access into tumour cells in much higher concentrations.
Unlike other ablative methods, ECT is non-destructive to healthy tissues
surrounding treated tumour sites and because it requires much lower
doses of chemotherapy drugs to achieve greater results it has an incredi-
bly low side effect proﬁle, making it a very attractive method of causing
ICD [200].
4.5. Photodynamic therapy (PDT)
PDT is an anticancer therapeuticmethod that uses the photo-sensitive
drug (eg. hypericin), which localizes in the ER [201]. When activated by
light of a suitable wavelength, it causes massive production of ROS at
the ER, resulting in ER membrane damage and BAX- and BAK-based mi-
tochondrial apoptosis [202–204]. Because of its ability to directly damage
the ER through ROS production, PDT is classed as a type II ICD inducer.
Other agents such as oxaliplatin, cyclophosphamide, mitoxantrone and
ionizing radiation are therefore type I ICD inducers as the resulting ER
stress is secondary to their primary mechanisms of action [88,99]. Type
II ICD inducers are thought to be more favourable due to the primary
ROS damage caused, making it harder for tumour cells to initiate ‘protec-
tive’ cellular mechanisms as may be the case with type I inducers. PDT
causes the release of a number of DAMPs as the stages of cell death prog-
ress; pre-apoptotic ecto-CRT; pre-apoptotic ATP; pre-apoptotic ecto-
HSP70; and late apoptotic passively released HSP70, HSP90 and CRT
[99,203,205,206]. In a clinical setting, PDTwas shown to increase the im-
mune recognition of TAAs and promote a better immunological response
than surgery [207]. In addition PDT lysates can cause DC maturation, IL-
12 production and the activation of macrophages [208,209]. While PDT
may seem to be the ICD inducer of choice it has one glaring drawback;
its application is limited to easily accessible malignancies on the skin.
5. Immune modulation & biological intervention
While ablative technologies are certainly effective at causing ICD and
the generation of anti-tumour speciﬁc immune response, they are often
not enough to cause total cancer elimination on their own, especially in
cases of metastatic disease. To potentiate their effects, the combination
of an immunemodulating agentwith an ablativemodality, is the logical
step forward. A summary of current and ongoing clinical trials combin-
ing ablativemethods with immunemodulators can be found in Table 1.
Broadly speaking immunemodulation can be split into 2 categories; im-
mune blockade and immune stimulation.
5.1. Immune blockade
The immune inhibitory receptors that have generated the most in-
terest in cancer therapy are CTLA-4 and PD-1, and the development of
checkpoint blocking antibodies has been largely focused on these two
receptors.
5.1.1. Cytotoxic T-Lymphocyte Antigen 4 blockade
Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) binds to two ligands,
CD80 (B7-1) and CD86 (B7-2), which it shares with the powerful co-
stimulatory molecule, CD28. Binding of CD28 causes increased produc-
tion of IL-2 and other pro-inﬂammatorymolecules, leading to increased
T cell proliferation [210,211] and prolonging T cell activity [212]. Con-
versely, CTLA-4 binding decreases the production of IL-2 [213], in-
creases the production of immunosuppressive cytokines such as TGF-
β [214] and causes T cell anergy by disrupting cell cycle progression
[213,215]. Given that CTLA-4 has much greater afﬁnity for the CD80/
CD86 receptors than CD28 it effectively out-competes with it for ligand
Table 1





Chemical agent Cancer type Study size Outcome Ref.
Ipilimumab – – Metastatic melanoma Phase III — 167 patients 10.1 month median overall survival [219]
Ipilimumab – Carboplatin, Dacarbazine Small Cell Lung
Cancer (SCLC)
Phase II — 130 patients irPFS of 6.2 month and median overall
survival of 12.9 months
[220]
Ipilimumab – W/wo dacarbazine Advanced melanoma Phase II — 72 patients 14.3 and 11.4 month median overall survival
respectively
[221]
Ipilimumab – Dicarbazine Metastatic melanoma Phase III — 251 patients 11.2 month median overall survival [222]
Ipilimumab Radiotherapy – Prostate Cancer Phase I/II — 33 patients PSA decline ≥ 50% and 21% positive
response
[223]
Ipilimumab Radiotherapy – Prostate cancer Phase II — 45 patients PSA decline ≥ 50% and median positive
response of 23 weeks
[224,225]
Ipilimumab Cryoablation – Breast cancer Pilot — 18 patients Study ongoing [228]
Ipilimumab ECT Bleomycin Advanced melanoma Pilot — 15 patients 67% local regression, 47% distal regression
and median survival of 12.4 months
[229]
Nivolumab – – NSCLC, melanoma,
renal cell carcinoma
Phase I — 296 patients NSCLC: 18%
Melanoma: 28%
Renal cell carcinoma: 27%
Positive durable response rate lasting over
12 months
[244]
Nivolumab – – Advanced melanoma Phase I — 107 patients 31% response rate and improved median
survival of 17 months
[245]
CT-011 – Gemcitabine Pancreatic cancer Phase II — 39 patients Study ongoing NCT01313416
CP-870,893 – – Advanced solid
malignancies
Phase I — 29 patients 14% overall positive response; 27% positive
response in melanoma patient sub-group
[277]
CP-870,893 Carboplatin and Paclitaxel Advanced solid
malignancies
Phase I — 32 patients 20% positive partial responses observed,
with another 40% displaying stable disease
[282]
SGN-40 – – Non-Hodgkin's
lymphoma
Phase I — 35 patients 37.5% positive objective response rate and
overall survival monitoring still ongoing
[280]
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but is hugely upregulated on their cell surfaces following TCR activation
[217]; this can be beneﬁcial in preventing runaway immune responses
like those associatedwith autoimmune diseases [218] but is undesirable
in terms of tumour elimination.
In the clinic, anti-CTLA-4 monoclonal antibodies (mAb) such as
Ipilimumab are showing promise as viable biological interventions. In
a large trial in patients with previously treated advanced metastatic
melanoma, treatment with Ipilimumab alone led to increased survival
in patients (10.1 months compared to untreated) [219]. Ipilimumab
has also been paired with traditional chemotherapy and results from
numerous studies have shown that Ipilimumab plus chemotherapy is
more effective than chemotherapy alone [220–222]. When combined
with radiation therapy, Ipilimumab also improves patient survival
when compared to Ipilimumab or radiation therapy alone [223–225]
and there are a number of ongoing larger scale clinical trials currently
ongoing using this examination. Cryoablation plus Ipilimumab has
shown promise in murine models by inducing potent anti-tumour im-
munity [226,227] and there is an ongoing pilot study in human patients
[228]. Other ablative technologies that display improved efﬁcacy when
combined with Ipilimumab include ECT [229] and there is an ongoing
trial in the Netherlands examining the beneﬁt of RFA plus Ipilimumab
treatment (NTR3488). One drawback to the use of anti-CTLA-4 antibod-
ies is that a number of studies have reported quite severe, dose depen-
dant, autoimmune side effects in small percentages of patients,
including; high grade enterocolitis [230], hypophysitis [231], and hepa-
titis [232].
5.1.2. Programme Cell Death Protein 1 blockade
ProgrammeCell Death Protein 1 (PD-1) is another important immune
inhibitory checkpoint receptor that is expressed on CD4+/CD8+ T cells,
natural killer T cells, B cells and activated monocytes [233,234]. It is part
of the same super family as CD28/CTLA-4 and shares structural homology
with both. As with CTLA-4 it has two ligands, PD-L1 (B7-H1) and PD-L2
(B7-DC) [235,236]. PD-L1 is expressed onmost cells and is greatly upreg-
ulated in many cancer types [65,237–239], suggesting its role in the ‘es-
cape’ of immune surveillance. PD-L2 is only known to be expressed on
activated macrophages, DCs, B cells and mast cells [240–242]. Uponbinding to either of its ligands, PD-1 can inhibit T cell proliferation in
the periphery and promote T cell anergy.While the exactmechanism be-
hind this action is not fully understood, some studies suggest that it is re-
lated to inhibition of pro-inﬂammatory cytokines such as IFN-γ [236,
243].
Nivolumab is a mAb developed to target the PD-1 receptor and has
shown exciting results in the clinical setting. Its efﬁcacy was evaluated
in a large study; 296 patients with various cancer types, with a positive
response rate of 20–25% across all cancer types [244]. Out of this group,
a cohort of 107 patients with advanced melanoma was chosen for fur-
ther follow-up. An objective response rate of 31% was observed for
this group, with an overall median improved survival of 17 months
[245]. To date anti-PD-1 mAb therapy has only been combined with
one ablative technology, radiotherapy. A murine study using an intra-
cranial glioma model showed that mice receiving a combination of
anti-PD-1 blockade and localized radiotherapy had a median survival
more than doublemice receiving either treatment alone [246]. An ongo-
ing phase 2 study looking at the potential of a chemotherapy/anti-PD-1
blockade combinationusing gemcitabine as the chemical intervention is
currently ongoing (NCT01313416) and suggests that anti-PD-1 therapy
should be combined with ECT in the future.
5.2. Immune stimulation
5.2.1. OX40 agonists
OX40 (CD137) is a member of the tumour necrosis factor receptor
(TNFR) family [247] and acts as a powerful co-stimulatory molecule
for CD4+ and CD8+ T cells [247,248]. Its ligand (OX40-L) is expressed
on a wide range of immune cells, such as activated B cells, dendritic
cells, and macrophages [249,250]. Ligation of OX40 has shown to be
critical for effective T cell activation and proliferation [251] and is espe-
cially important in the generation of CD4+ memory T cell populations
[252,253]. Anti-OX40 agonist mAbs have been used in a number of an-
imalmodels and displayed the ability to cause complete tumour regres-
sion by inducing anti-tumour immune responses [254–256]. Anti-OX40
agonists have been used in combination with the chemotherapeutic
agent cyclophosphamide in a melanoma mouse model. Neither treat-
ment alone provided much protection against tumour growth but
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nation. This result was shown to be achieved through the generation of
potent anti-tumour immune response [257]. In this respect anti-OX40
agonists should be used in conjunction with ECT in the future. When
used in combination with radiation therapy, anti-OX40 agonists signiﬁ-
cantly boost tumour free survival in a CD8+ T cell dependant manner
[258,259]. Anti-OX40 agonists have not been used in human trials as
of yet but could represent the future of anti-cancer immune stimulation.
5.2.2. CD40 agonists
Another member of the TNFR family that is being looked at for its
ability to overcome and reverse the immunosuppressive environment
generated by tumours is the CD40 receptor. CD40 is a transmembrane
protein that is expressed on a number of immune cells, including; B
cells, monocytes and APCs (DCs and macrophages) [260–263]. Its li-
gand, CD40-L (CD154), is primarily expressed on activated T cells
[264]. CD40/CD40-L binding on the surface of APCs plays a critical role
in generating a tumour speciﬁc immune response, upregulating the ex-
pression of co-stimulatory molecules CD80 and CD86 on APCs [261,
265]. It causes the increased production of the T-cell stimulatory cyto-
kine IL-12 [266], promoting the maturation of naïve T cells into CD4+
T cells [267], which in turn drives the secretion of IFN-γ and TNF-α
[268,269]. Interestingly, CD40 is also expressed in all B cell malignancies
as well as on the surface of many solid tumour types and exogenous ac-
tivation leads to the inhibition of tumour growth by activating apoptotic
pathways and improving the cytotoxicity of CD8+ T cells [270–274].
Given this potential, a lot of effort is being put into developing anti-
CD40 agonistic mAbs. CP-870,893, a fully human anti-CD40 mAb, has
shown single agent activity in a wide range of tumour types, including
colorectal, melanoma and leukaemia [275–277]. CP-870,893 anti-
tumour activity was shown to include both non-immune and immune
mediated pathways; more detailed analysis revealed that the immune
mechanism involved the rapid expansion of B cell populations and sub-
sequent up-regulation of co-stimulatorymolecule CD86 on their surface
[277]. SGN-40, a humanized anti-CD40 mAb, has exhibited efﬁcacy in
inhibiting tumour growth in preclinical myeloma and lymphoma
models [278,279]. A phase 1 trial, using SGN-40 in the treatment of
non-Hodgkin's lymphoma, showed positive objective response in 15%
of patients [280].
CP-870,893 in combination with radiation therapy has been used in
murine lymphoma models. Radiation or antibody only was ineffective
but together they caused signiﬁcantly increased survival, with this re-
sult being accredited to the generation of CD8+ T cell response, that
was not observed in non-tumour bearing mouse receiving the same
treatment [281]. CP-870,893 has been pairedwith a chemotherapy reg-
imen (carboplatin and paclitaxel) in a phase 1 study; 20% of patients re-
ceiving the combination had partial responses and a further 40% had
stable disease following treatment. These results correlated with an in-
crease in serum IL-6 and TNF-α levels [282]. With this in mind, anti-
CD40 agonists seem synergistic with chemotherapy, possibly due to
the chemo-induced release of DAMPs into the tumour environment.
Combining with ECT could potentiate this efﬁcacy even further.
6. Conclusion
Signiﬁcant strides have beenmade in recent years in understanding
the intricate relationship between the immune system and cancer. We
now have a better picture of the mechanisms used by the immune sys-
tem to detect and eliminate cancer, as well as the ways in which cancer
cells can evade andmanipulate it. The emergence of ICD andDAMPs has
opened our eyes to the fact that causing cancer cell death is simply not
enough; the type of cell death and the method by which it is achieved
are crucial if we are to get the best responses. Conventional cancer ther-
apies tend to focus on either causingmaximal cancer cell death ormod-
ulating the immunological response of the body to the cancer. Going
forward, these two strategies must be married together; developingtreatment regimens thatmaximise cancer cell death in an immunogenic
manner and harnessing the formidable power of the immune system
will lead to powerful results. Initial data from current clinical trials, com-
bining these two modalities, is very positive and shows that we are al-
ready on the right path. Emerging ablative technologies such as ECT
showgreat promise given its low side effect proﬁle and its ability to gen-
erate ICD; further work combining ECT and immune modulators could
yield very positive outcomes in the clinic.Acknowledgements
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